All News

Found 20,605 articles

• Massive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug Matching and Beyond

  1/4/2023

  Massive Bio , a leader in AI-powered cancer treatment, today announced plans to launch a new AI-powered drug matching product in 2023 that will enable oncologists to proactively identify more cancer treatment options for their patients, including recently approved drugs as well as active clinical trials.

• Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

  1/4/2023

  Immunitas Therapeutics today announced the first patient has been dosed in a Phase 1/2a clinical trial evaluating use of novel cancer immunotherapeutic IMT-009 in solid tumors and hematologic malignancies.

• Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer

  1/4/2023

  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it has enrolled and randomised over 50% of the planned 154 patients in the TACTI-003 Phase IIb trial.

• Celularity Appoints Paul Graves as Chief Communications Officer

  1/4/2023

  Celularity Inc., a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023.

• Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T Process Qualification Run Completed

  1/4/2023

  Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its second Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells.

• Pharnext Strengthens its Senior Leadership Team with the Appointment of Scott Johnson as VP, Head of Quality

  1/4/2023

  Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the appointment of Scott Johnson as VP, Head of Quality.

• Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines

  1/3/2023

  Abintus Bio Appoints Hebrew University Researcher Lior Nissim, Ph.D., As Head of Synthetic Biology and Concurrently Enters Agreement for Next-Generation, Synthetic Biology Technology to Enable In Vivo Genetic Medicines.

• MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer

  1/3/2023

  MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s manufacturing, supply chain, procurement, quality, and regulatory functions.

• Athenex Announces MHRA Decision on Oral Paclitaxel

  1/3/2023

  Athenex, Inc. announced that its proprietary Oral Paclitaxel formulation did not receive regulatory approval from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for metastatic breast cancer based solely on CMC issues.

• Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinson’s Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics

  1/3/2023

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson’s disease psychosis (PDP) treated with NUPLAZID® (pimavanserin) compared to other atypical antipsychotics over 12 months and across various subgroups.

• Johnson & Johnson Announces Quarterly Dividend for First Quarter 2023

  1/3/2023

  Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2023 of $1.13 per share on the company’s common stock.

• ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer

  1/3/2023

  ADC Therapeutics SA announced the appointment of industry veteran Mohamed Zaki, MD, PhD, as Chief Medical Officer, effective January 3, 2023. He will serve on the Company’s executive leadership team.

• Align Technology to Announce Fourth Quarter and 2022 Results on February 1, 2023

  1/3/2023

  Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® system of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report fourth quarter and 2022 financial results on Wednesday, February 1, 2023, after the close of market. Financial results will be released at 4:00 p.m. ET.

• Bavarian Nordic Enters Agreement Valued up to USD 83 Million with the U.S. Department of Defense to Further Advance the Development of Equine Encephalitis Virus Vaccine

  12/23/2022

  Bavarian Nordic A/S announced a new agreement with the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, for the advanced development of MVA-BN® WEV, a prophylactic vaccine candidate against Western, Eastern and Venezuelan equine encephalitis virus, which can cause a rare, but potentially deadly mosquito-borne illness in humans.

• Point-of-Care Testing (POCT) Market Size To Attain USD 103.2 Bn By 2030

  12/23/2022

  The global point-of-care testing (POCT) market size accounted for USD 45.03 billion in 2022 and is expected to attain around USD 103.2 billion by 2030 with a noteworthy CAGR of 10.92% from 2022 to 2030.

• Galapagos announces changes to Executive Committee

  12/22/2022

  Galapagos NV announced changes in the Executive Committee effective 1 January 2023.

• Stemtech Cororation Announces Life Factor Research Obtains First Production Contract With New Customer

  12/22/2022

  Stemtech Corporation (OTCQB:STEK) today announced that Life Factor Research, the Research and Development Division of Stemtech, has acquired its first contract to produce a while label product for a new client.

• Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

  12/22/2022

  Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has completed the planned enrollment of subjects in the global, randomized, double-blind Phase 3 clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN ® RSV in adults ≥60 years of age.

• Johnson & Johnson Completes Acquisition of Abiomed

  12/22/2022

  Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc.

• Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

  12/21/2022

  Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 9:00 a.m. Pacific Time, followed by a question and answer session.